Optimizing ART With Novel HIV Agents

CCO Infectious Disease Podcast

Inhalt bereitgestellt von Clinical Care Options, LLC and Clinical Care Options. Alle Podcast-Inhalte, einschließlich Episoden, Grafiken und Podcast-Beschreibungen, werden direkt von Clinical Care Options, LLC and Clinical Care Options oder seinem Podcast-Plattformpartner hochgeladen und bereitgestellt. Wenn Sie glauben, dass jemand Ihr urheberrechtlich geschütztes Werk ohne Ihre Erlaubnis nutzt, können Sie dem hier beschriebenen Verfahren folgen https://de.player.fm/legal.

3M ago 12:32

MP3•Episode-Home

In this episode, Gregory Huhn, MD, MPHTM, presents a case study of a person with a long HIV treatment history, exploring when and how to consider agents with novel mechanisms of action.

Listen as he discusses:

The importance of engaging with patients to understand their perspectives and improve their satisfaction with their HIV care
Options in people with multiclass resistance
Studies of agents with novel mechanisms of action:
- BRIGHTE (fostemsavir)
- TMB-301/-311 (ibalizumab)
- CAPELLA (lenacapavir)

Faculty

Gregory Huhn, MD, MPHTM,
Interim Chief, Division of Infectious Diseases
Senior Director of HIV Services
Cook County HIV Integrated Programs
Interim Medical Director, The RMR CORE Center
Professor, Division of Infectious Diseases
Rush University Medical Center
Chicago, Illinois

Follow along with the slides.
https://bit.ly/4fHmxg5

Get access to all of our new podcast episodes. Subscribe to the CCO Infectious Disease podcast on Apple Podcasts, Google Podcasts, or Spotify.

412 Episoden

#Science #Fitness #Biology #Higher Education #Podcasting Education #Medicine #Clinical Care Options, LLC #Clinical Care Options #HIV #On Covid19 #CME #Hepatitis B #Hbv #Infectious Disease Medical Education #Id Medical Education #Coronavirus #Hepatitis C #Hcv